Schedule 13G ownership disclosure

CARISMA THERAPEUTICS INC

Common Stock, $0.001 par value · CUSIP: 14216R101

Event date: 2025-03-31

Filing-level shares
1,855,871.00
Percent of class
4.4%
  • AbbVie Biotechnology Ltd.

    Shares: 1,855,871.00 · Class: 4.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-039436
Form type
SCHEDULE 13G/A
Filer
AbbVie Biotechnology Ltd
CIK
CIK 2014668
Filed
Apr 25, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub